PCI Pharma Services Announces Bottling Line Expansion to Support Customer Needs
PCI Pharma Services recently announce the expansion of its bottling line capacity at its Commercial Packaging site in Rockford, IL. Construction of the additional packaging suites began in March 2018 to add considerable footprint for primary and secondary packaging operations equipped with high speed tablet filling, cartoning, as well as in-line serialization and aggregation in support of increased customer demand. The new expansion will grow the robust bottling operation in Rockford by producing an extra 100 million bottles per year.
“I am pleased to share this news regarding our continued investment to support the needs of our customers,” noted Angella Sutthiwan, Vice President and General Manager for PCI’s Rockford location. “Choosing the right contract packaging business partner, one that can consistently and reliably deliver high quality product quickly, while providing the flexibility to manage the peaks and valleys of changing forecasts, is critical to our customers. This multi-million dollar investment demonstrates our commitment to providing both operational flexibility and expansive capacity in meeting those demands in order to bring life-saving medicines to patients around the world.”
PCI’s investment at the Rockford location is the latest in a series of capacity expansion initiatives across its worldwide network, including multiple facility enlargements, Cold Chain and Ultra Cold storage extension, installations of additional packaging lines, as well as significant expansion of its best-in-class Serialization solutions. To further support its existing Biotech infrastructure, PCI’s Commercial Packaging site in Philadelphia, PA recently announced a major $20 million investment in commercial packaging, as well as expanded Cold Chain capacity at numerous global locations.
PCI supports medicines destined to reach more than 100 countries across the world, providing industry-leading services for the clinical and commercial packaging of a diverse portfolio of products and specialized delivery forms. These include, but are not limited to, solid oral dose, powders, semisolids, parenterals and injectibles, with key specialization in potent compounds, cold chain products, controlled substances, and biologics. For more information, visit click here.
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.
Total Page Views: 1816
